OptiScan Biomedical Corporation has developed an innovative monitoring platform for use in hospital intensive care units (ICU) to support clinicians in detecting changes more rapidly in critically ill patients, enabling more timely intervention. The OptiScanner® platform is presently focused on delivering automated bedside glucose monitoring to support clinicians’ reach and maintain the right level of glucose control.
Latest funding size
Time since last funding
|about 1 year|
|Morgenthaler Ventures, Wexford Capital, Johnson & Johnson Development Corporation, MedVenture Associates|